![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MYB |
Gene summary for MYB |
![]() |
Gene information | Species | Human | Gene symbol | MYB | Gene ID | 4602 |
Gene name | MYB proto-oncogene, transcription factor | |
Gene Alias | Cmyb | |
Cytomap | 6q23.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P10242 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4602 | MYB | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.28e-12 | -4.18e-01 | 0.0155 |
4602 | MYB | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.82e-04 | -4.60e-01 | -0.1808 |
4602 | MYB | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.87e-05 | -5.25e-01 | -0.1207 |
4602 | MYB | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.52e-03 | -3.00e-01 | 0.0674 |
4602 | MYB | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.87e-27 | -6.64e-01 | 0.3005 |
4602 | MYB | F007 | Human | Colorectum | FAP | 3.46e-04 | -3.43e-01 | 0.1176 |
4602 | MYB | A001-C-207 | Human | Colorectum | FAP | 3.60e-05 | -3.00e-01 | 0.1278 |
4602 | MYB | A015-C-203 | Human | Colorectum | FAP | 3.78e-28 | -3.53e-01 | -0.1294 |
4602 | MYB | A015-C-204 | Human | Colorectum | FAP | 3.61e-06 | -3.38e-01 | -0.0228 |
4602 | MYB | A014-C-040 | Human | Colorectum | FAP | 1.96e-03 | -3.15e-01 | -0.1184 |
4602 | MYB | A002-C-201 | Human | Colorectum | FAP | 1.45e-13 | -3.14e-01 | 0.0324 |
4602 | MYB | A002-C-203 | Human | Colorectum | FAP | 3.70e-07 | -2.86e-01 | 0.2786 |
4602 | MYB | A001-C-119 | Human | Colorectum | FAP | 1.38e-06 | -3.48e-01 | -0.1557 |
4602 | MYB | A001-C-108 | Human | Colorectum | FAP | 1.36e-17 | -3.39e-01 | -0.0272 |
4602 | MYB | A002-C-205 | Human | Colorectum | FAP | 4.88e-20 | -3.57e-01 | -0.1236 |
4602 | MYB | A001-C-104 | Human | Colorectum | FAP | 2.71e-08 | -2.79e-01 | 0.0184 |
4602 | MYB | A015-C-005 | Human | Colorectum | FAP | 9.20e-03 | -1.67e-01 | -0.0336 |
4602 | MYB | A015-C-006 | Human | Colorectum | FAP | 2.37e-16 | -4.75e-01 | -0.0994 |
4602 | MYB | A015-C-106 | Human | Colorectum | FAP | 4.39e-10 | -1.41e-01 | -0.0511 |
4602 | MYB | A002-C-114 | Human | Colorectum | FAP | 2.27e-17 | -3.41e-01 | -0.1561 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004352310 | Oral cavity | OSCC | regulation of neuron apoptotic process | 111/7305 | 212/18723 | 5.12e-05 | 4.27e-04 | 111 |
GO:000762316 | Oral cavity | OSCC | circadian rhythm | 110/7305 | 210/18723 | 5.40e-05 | 4.48e-04 | 110 |
GO:000164910 | Oral cavity | OSCC | osteoblast differentiation | 118/7305 | 229/18723 | 7.51e-05 | 5.85e-04 | 118 |
GO:004352518 | Oral cavity | OSCC | positive regulation of neuron apoptotic process | 37/7305 | 58/18723 | 1.15e-04 | 8.35e-04 | 37 |
GO:00329229 | Oral cavity | OSCC | circadian regulation of gene expression | 40/7305 | 68/18723 | 7.28e-04 | 3.98e-03 | 40 |
GO:20002092 | Oral cavity | OSCC | regulation of anoikis | 17/7305 | 24/18723 | 1.59e-03 | 7.56e-03 | 17 |
GO:000301214 | Prostate | Tumor | muscle system process | 105/3246 | 452/18723 | 7.44e-04 | 5.14e-03 | 105 |
GO:014001415 | Skin | cSCC | mitotic nuclear division | 149/4864 | 287/18723 | 3.59e-21 | 6.43e-19 | 149 |
GO:190285016 | Skin | cSCC | microtubule cytoskeleton organization involved in mitosis | 85/4864 | 147/18723 | 2.66e-16 | 2.39e-14 | 85 |
GO:000705215 | Skin | cSCC | mitotic spindle organization | 73/4864 | 120/18723 | 7.81e-16 | 6.80e-14 | 73 |
GO:000705115 | Skin | cSCC | spindle organization | 96/4864 | 184/18723 | 2.59e-14 | 1.77e-12 | 96 |
GO:00482854 | Skin | cSCC | organelle fission | 197/4864 | 488/18723 | 1.51e-12 | 8.36e-11 | 197 |
GO:00002803 | Skin | cSCC | nuclear division | 178/4864 | 439/18723 | 1.17e-11 | 5.93e-10 | 178 |
GO:009030716 | Skin | cSCC | mitotic spindle assembly | 41/4864 | 65/18723 | 3.34e-10 | 1.37e-08 | 41 |
GO:005122513 | Skin | cSCC | spindle assembly | 60/4864 | 117/18723 | 4.15e-09 | 1.41e-07 | 60 |
GO:007099729 | Skin | cSCC | neuron death | 133/4864 | 361/18723 | 2.91e-06 | 4.58e-05 | 133 |
GO:199082317 | Skin | cSCC | response to leukemia inhibitory factor | 42/4864 | 95/18723 | 8.79e-05 | 8.27e-04 | 42 |
GO:199083016 | Skin | cSCC | cellular response to leukemia inhibitory factor | 41/4864 | 94/18723 | 1.53e-04 | 1.35e-03 | 41 |
GO:190121627 | Skin | cSCC | positive regulation of neuron death | 42/4864 | 97/18723 | 1.56e-04 | 1.37e-03 | 42 |
GO:190121426 | Skin | cSCC | regulation of neuron death | 112/4864 | 319/18723 | 1.71e-04 | 1.48e-03 | 112 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04151 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa041511 | Colorectum | FAP | PI3K-Akt signaling pathway | 75/1404 | 354/8465 | 1.23e-02 | 4.19e-02 | 2.55e-02 | 75 |
hsa041512 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
hsa041513 | Colorectum | CRC | PI3K-Akt signaling pathway | 64/1091 | 354/8465 | 2.70e-03 | 1.77e-02 | 1.20e-02 | 64 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYB | SNV | Missense_Mutation | c.308N>C | p.Val103Ala | p.V103A | P10242 | protein_coding | deleterious(0.02) | probably_damaging(0.965) | TCGA-A2-A1FZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Arimidex | SD | |
MYB | SNV | Missense_Mutation | c.916N>A | p.Glu306Lys | p.E306K | P10242 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
MYB | SNV | Missense_Mutation | c.1575C>G | p.Asn525Lys | p.N525K | P10242 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MYB | SNV | Missense_Mutation | c.403C>T | p.His135Tyr | p.H135Y | P10242 | protein_coding | deleterious(0) | benign(0.019) | TCGA-C8-A133-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
MYB | SNV | Missense_Mutation | c.1570T>G | p.Leu524Val | p.L524V | P10242 | protein_coding | tolerated(0.05) | probably_damaging(0.995) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD | |
MYB | insertion | Frame_Shift_Ins | novel | c.281_282insT | p.Trp95LeufsTer37 | p.W95Lfs*37 | P10242 | protein_coding | TCGA-A2-A0ET-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | ||
MYB | deletion | Frame_Shift_Del | novel | c.1946_1947delNN | p.Gln649ArgfsTer7 | p.Q649Rfs*7 | P10242 | protein_coding | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
MYB | insertion | Frame_Shift_Ins | novel | c.1243_1244insCAACCTCTAGCACTATTAAAAACAGGGTCTTGCA | p.Phe415SerfsTer13 | p.F415Sfs*13 | P10242 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
MYB | deletion | Frame_Shift_Del | c.1710delN | p.Phe571LeufsTer11 | p.F571Lfs*11 | P10242 | protein_coding | TCGA-BH-A0E7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |||
MYB | insertion | Frame_Shift_Ins | novel | c.418_419insCA | p.Glu141GlnfsTer81 | p.E141Qfs*81 | P10242 | protein_coding | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4602 | MYB | CLINICALLY ACTIONABLE | RETINOID | 8670250 | ||
4602 | MYB | CLINICALLY ACTIONABLE | 12-O-TETRADECANOYLPHORBOL-13-ACETATE | 12354938 | ||
4602 | MYB | CLINICALLY ACTIONABLE | 5-FLUOROURACIL | FLUOROURACIL | 15001837 | |
4602 | MYB | CLINICALLY ACTIONABLE | DOXORUBICIN | DOXORUBICIN | 15001837 | |
4602 | MYB | CLINICALLY ACTIONABLE | G4460 | |||
4602 | MYB | CLINICALLY ACTIONABLE | TAXOL | PACLITAXEL | 15001837 |
Page: 1 |